Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines

Figure 1

Antitumor effect of systemic administration of high-dose adjuvants. C57BL/6 or BALB/c mice (𝑛=6) were s.c. inoculated with 3 × 10⁴ TC-1 (a, b) or 5 × 10³ 12B1 cells (c, d) and immunized by a gene gun with 1 μg of pBSC/E7GGG.LAMP three and ten days later or with 2 μg of pBSC/bcr-abl three, six, and ten days later, respectively. The pBSC plasmid was used as a negative control. CpG-ODN (50 μg; a, c) or LMS (200 μg; b, d) was i.p. injected on the days of DNA vaccination. No. of mice with a tumor/no. of mice in the group is indicated. Bars: ±SD; *𝑃<0.05; **𝑃<0.01.

(a)

(b)

(c)

(d)